Lilly’s Rheumatoid Arthritis Drug, Combined With Remdesivir, Benefits Covid-19 Patients Who Need Oxygen

Lilly announced additional findings indicating that its rheumatoid arthritis drug, baricitinib, may improve the health of severe Covid-19 patients when used in combination with Gilead Science’s antiviral drug remdesivir.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive